ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2089

Diagnostic Performance of ACR and NICE Criteria for Hip Osteoarthritis

Jos Runhaar1, Dieuwke Schiphof1, Qiuke Wang1, Margreet Kloppenburg2, Maarten Boers3, Hans Bijlsma4 and Sebastia Bierma-Zeinstra1, and the CREDO expert group, 1Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, 2Leiden University Medical Center, Leiden, Netherlands, 3Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, 4UMCU, Utrecht, Utrecht, Netherlands

Meeting: ACR Convergence 2024

Keywords: Diagnostic criteria, Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Osteoarthritis – Clinical Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Available criteria for diagnosis or classification of hip osteoarthritis (OA) have been poorly validated. The few validation studies available all used radiographic features of hip OA as reference standard, despite the clinical importance of hip symptoms. Therefore, the current study aimed to assess the diagnostic performance of the clinical ACR criteria and the NICE criteria against expert-based diagnosis of clinically relevant hip OA.

Methods: The CHECK study enrolled Dutch individuals aged 45-65 years with pain/stiffness in the knees and/or hips, prior to or within 6 months after their first consultation for these complaints with a general practitioner (GP). Individuals were excluded if their complaints were due to other causes than OA. All participants were assessed at baseline and after 2, 5, 8, and 10 years, with validated questionnaires (patient characteristics and knee/hip symptoms), physical examination (joint range of motion, pain at passive motion), and radiography (Kellgren & Lawrence [KL] grading). For the current study, all baseline symptomatic hips with follow-up data available were selected for analyses.
In pairs and based on the clinical data obtained at year 5 (T5) through year 10 (T10), 24 clinical experts (13 GPs, 6 rheumatologists, and 5 orthopedists) determined the presence of ‘clinically relevant hip OA’ over the follow-up period. Experts relied on their clinical expertise for diagnosis, as no definition for ‘clinically relevant hip OA’ was provided. First, experts evaluated all hips individually, after which a consensus meeting was held to discuss cases with conflicting diagnoses.
At each time point separately, the fulfilment of the clinical ACR criteria (hip pain + internal rotation < 15° + flexion of the hip ≤115°; or hip pain + internal rotation ≥15°, pain at internal rotation, stiffness ≤60 min + age >50 years) and the NICE criteria (activity related hip pain + no morning stiffness or < 30 minutes + aged ≥45 years) was determined for each hip. Next, with the expert-based diagnosis of ‘clinically relevant hip OA’ (present/absent) as reference standard, test characteristics were determined for each set of criteria in 3 definitions of a positive test, i.e. meeting a set of criteria at one, two, or at all three time points.

Results: In total, 562 hips were available for analyses. At T5, mean age was 60.3 ± 5.1 years, mean BMI was 26.6 ± 4.1 kg/m2, and 83% were female. Radiographic hip OA (KL≥2) was present in 22% of hips at T5, 28% at T8, and 49% at T10. ‘Clinically relevant hip OA’ was diagnosed in 27% of all hips. Compared to the ACR criteria, more hips fulfilled the NICE criteria once, at two time points, and at all time points. The ACR criteria outperformed the NICE criteria on specificity and positive predictive value, while sensitivity and negative predictive value were highest for the NICE criteria.

Conclusion: With clinical diagnosis as reference standard, the ACR criteria appear better suited for patient selection for clinical studies, where enrollment of a homogeneous sample of patients with a high probability of having OA is prioritized, at the cost of high false-negative rates. Conversely, NICE criteria appear better suited for clinical diagnosis, where one would like to minimize false-negatives.

Supporting image 1

Diagnostic abilities of ACR and NICE criteria for hip OA against clinical experts’ diagnosis.


Disclosures: J. Runhaar: None; D. Schiphof: None; Q. Wang: None; M. Kloppenburg: None; M. Boers: Celltrion, 2, Novartis, 2, 6, Pfizer, 6; H. Bijlsma: None; S. Bierma-Zeinstra: None.

To cite this abstract in AMA style:

Runhaar J, Schiphof D, Wang Q, Kloppenburg M, Boers M, Bijlsma H, Bierma-Zeinstra S. Diagnostic Performance of ACR and NICE Criteria for Hip Osteoarthritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/diagnostic-performance-of-acr-and-nice-criteria-for-hip-osteoarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diagnostic-performance-of-acr-and-nice-criteria-for-hip-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology